Cost of medication
The cost of the drug is in addition to consultation, diagnostic and injection fees. There are several drugs used to treat macular disease. These are administered as eye injections, also called intravitreal injections or IVI.
Lucentis and Eylea
- wet (neovascular) age-related macular degeneration (AMD)
- diabetic macular oedema (DMO) and
- retinal vein occlusion (RVO).
The PBS subsidy for the drug Lucentis has been extended for the treatment of other macular conditions similar to wet AMD, where abnormal blood vessels grow under the macula.
The drug Ozurdex is registered by the TGA and subsidised by the PBS for the treatment of:
In Australia, Avastin can be used to treat people with macular disease who aren’t eligible for PBS subsidised medications.
Avastin isn’t registered by the TGA nor subsidised by the PBS for use in the eye. The cost is usually around $50 per dose.
The use of Avastin to treat macular disease is known as “off-label” use.
Subsidies for Lucentis, Eylea and Ozurdex
Under the PBS, the subsidised cost of Lucentis, Eylea and Ozurdex in 2021 per prescription (one dose) is:
- $6.60 (concession card holder) or
- $41.30 (non-concession).
The PBS Safety Net will apply once the costs in a calendar year for all PBS drugs exceed:
- $316.80 (concession) or
- $1,497.20 (non-concession).
After reaching the PBS Safety Net, each subsequent PBS script will be free (concession) or $6.60 (non-concession) for the remainder of the calendar year.
Much of the information in this section is available in a fact sheet. You can download the Eye Injection Costs and Rebates fact sheet below, or order a copy to be sent to you.